Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Builds Vaccine Portfolio With Affinivax Pneumococcal Candidate

Executive Summary

Despite one recent setback, Astellas is continuing to expand its vaccines business through a new global deal for Affinivax's lead MAPS pneumococcal product, in a move that builds on earlier research links between the companies.

You may also be interested in...



Affinivax's 24-Valent Pneumococcal Vaccine Targets Growing And Changing Market

A potential next-generation, 24-valent, pneumococcal vaccine in development by Affinivax and Astellas has shown strong immunogenicity in a Phase II study and is preparing to enter pivotal Phase III trials; if successful, it will target a growing market currently dominated by big pharma players.

With Prevnar Challenger Fully Funded, Affinivax Raises $120m For Other Novel Vaccines

Astellas is funding the company’s Phase II vaccine against 24 pneumococcal serotypes. Affinivax will use its series B venture cash to advance its MAPS vaccines for bacterial and viral infections and cancer.

Affinivax’s MAPS Vaccine Technology Reaches Clinic In Under Five Years

Funded entirely by grants and partnerships to date, Affinivax’s pneumococcal vaccine candidate has begun a Phase I/II study less than five year’s after the biotech’s founding. Firm thinks its technology may eventually apply to immuno-oncology as well.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel